Novocure’s CEO to Retire, CFO Ashley Cordova to Take Over Role

Novocure’s CEO Asaf Danziger announced that he will retire at the end of 2024 and the company’s chief financial officer (CFO) Ashley Cordova will succeed him as its next chief executive.
 
Danziger has been Novocure’s chief exec since 2002. He will serve as senior advisor into early 2026, and continue as a member of the company’s board of directors. The changes will take effect on January 1, 2025.
 
Danziger was Novocure’s fourth employee, leading the company from preclinical development through regulatory approvals and product commercialization. He helped to grow Novocure into an organization with more than $500 million in annual global revenue and over 1,500 employees.
 
“It has been a special honor and one of the greatest privileges of my life to serve as Novocure’s CEO for the last 22 years,” said Danziger. “I am very proud of the organization we have built starting with just a few people in a preclinical lab to where we stand today—treating thousands of patients living with aggressive forms of cancer. Now, we are poised to expand the potential of Tumor Treating Fields therapy to many more people. I am confident that under Ashley’s leadership Novocure is well positioned to achieve great things.”
 
Incoming CEO Ashley Cordova has been Novocure’s CFO since September 2020. She joined the company in 2014, and throughout her tenure has been crucial in building Novocure’s global organization and preparing it for the next stage of growth. Before Novocure, Cordova served in financial roles at Zoetis Inc. from 2012 to 2014 and Pfizer from 2005 to 2012.
 
“It has been a professional and personal highlight for me to work hand in hand with Asaf over the past 10 years and I am grateful for his leadership and partnership,” said Cordova. “Novocure’s mission to extend survival in aggressive forms of cancer is as significant today as it was 20 years ago, and I am excited to take on the role of CEO at this pivotal time as we look to expand the reach of Tumor Treating Fields therapy across multiple solid tumor indications.”
 
The company also revealed that Wilco Groenhuysen will step down as chief operating officer (COO) effective October 1, 2024. Mukund Paravasthu, who joined Novocure in 2020 and currently serves as senior VP, Product Development, will expand his current responsibilities and transition into the role of COO.